1. May 10, 2021

    Rifapentine-based regimen may allow for shorter course in tuberculosis

    Treatment with rifapentine-based regimen for 4 months was found to be noninferior to the standard 6-month regimen in patients with tuberculosis, according to a study.

    In this open-label, phase 3, randomized, controlled trial, 2234 patients with newly diagnosed pulmonary tuberculosis were asse…


Conference Roundup

  1. Apr 13, 2021

Investigational therapy improves overall survival in metastatic uveal melanoma

Tebentafusp (IMCgp100; Immunocore) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in patients with metastatic uveal melanoma, according to Phase 3 clinical trial results presented at…

Journal Scan